CESAME - Cancer and Increased Risk Associated with Inflammatory Bowel Disease in France

Head :Beaugerie Laurent, UMRS-S 707

Last update : 12/01/2017 | Version : 2 | ID : 60029

General	
Identification	
Detailed name	Cancer and Increased Risk Associated with Inflammatory Bowel Disease in France
Sign or acronym	CESAME
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	Accord CNIL 784332
General Aspects	
Medical area	Cancer research
Health determinants	Genetic Nutrition Social and psychosocial factors
Keywords	lymphoma, Health episodes, incidence, mortality
	lymphoma, mean episodes, meldenee, mortailey
Scientific investigator(s) (Contact)	lymphoma, mean episodes, incluence, mortailey
Scientific investigator(s)	Beaugerie
Scientific investigator(s) (Contact)	
Scientific investigator(s) (Contact) Name of the director	Beaugerie
Scientific investigator(s) (Contact) Name of the director Surname	Beaugerie Laurent
Scientific investigator(s) (Contact) Name of the director Surname Email	Beaugerie Laurent laurent.beaugerie@sat.aphp.fr
Scientific investigator(s) (Contact) Name of the director Surname Email Unit	Beaugerie Laurent laurent.beaugerie@sat.aphp.fr UMRS-S 707
Scientific investigator(s) (Contact) Name of the director Surname Email Unit Organization	Beaugerie Laurent laurent.beaugerie@sat.aphp.fr UMRS-S 707
Scientific investigator(s) (Contact) Name of the director Surname Email Unit Organization Collaborations	Beaugerie Laurent laurent.beaugerie@sat.aphp.fr UMRS-S 707

	FERRING
Governance of the database	
Sponsor(s) or organisation(s) responsible	INSERM - Institut National de Santé et Recherche Médicale
Organisation status	Public
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Inclusion method: Prospective Other bodies active in creating this cohort: URC, AFA, ANGH, CREGG, FFCD, GETAID, GFHGNP, SFED, SNCP, SNFGE, TLA REVUE FRANCOPHONE DE GASTRO-ENTEROLOGIE, PHARMACEUTICAL COMPANIES INVOLVED IN THE TREATMENT OF IBD, L'ASSOCIATION FRANÇAISE DES MALADES ATTEINTS DE MICI, REGIONAL FMC GASTROENTEROLOGY ASSOCIATIONS
Database objective	
Main objective	General objective: To test the hypothesis that the use of immunosuppressants (IS) for inflammatory bowel disease (IBD) leads to an increased risk of lymphoma in a cohort population. Secondary objective: to assess - relative risk associated with IS treatment for all cancers, to assess the standardised incidence rate for all other cancers observed during IBD; -The increased risk of colorectal cancer associated with extensive and former colonic inflammation for ulcerative colitis (UC) and Crohn's disease: - Increased risk of ileal adenocarcinoma associated with chronic ileal inflammation in Crohn's disease; - Evaluation of mortality of patients with IBD diseases and risk factors; - Protective role of salicylates, pregnancy and malformation syndromes.

Inclusion criteria	Subjects with IBD (Crohn's disease, ulcerative colitis, and indeterminate colitis) defined according to the usual diagnostic criteria, who attended consultation at least once between May 2005 and May 2006.
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	Multicentric cohort throughout France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	05/2006
Date of last collection (YYYY or MM/YYYY)	12/2007
Size of the database	
Size of the database (number of individuals)	Greater than 20 000 individuals
Details of the number of individuals	20819
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Biological data
Clinical data (detail)	Direct physical measures Medical registration
Biological data (detail)	Type of samples taken: tumour tissues for cancer cases

Presence of a biobank	Yes
Contents of biobank	Tissues
Details of biobank content	CANCER TISSUE BANK: LYMPH NODE SAMPLES FOR LYMPHOMA CASES, COLON CANCER
Health parameters studied	Health event/morbidity Health event/mortality
Procedures	
Participant monitoring	Yes
Details on monitoring of participants	Follow-up duration: 29 months
Links to administrative sources	Yes
Linked administrative sources (detail)	CépiDc
Promotion and access	
Promotion and access Promotion	
	http://www.hal.inserm.fr/CESAME
Promotion	http://www.hal.inserm.fr/CESAME List of publications in HAL
Promotion Link to the document	
Promotion Link to the document Description	List of publications in HAL <u>http://www.ncbi.nlm.nih.gov/pubmed/?</u> <u>term=%28cesame+AND+Beaugerie[Author]%29+</u>
PromotionLink to the documentDescriptionLink to the document	List of publications in HAL <u>http://www.ncbi.nlm.nih.gov/pubmed/?</u> <u>term=%28cesame+AND+Beaugerie[Author]%29+</u> <u>OR+22157331[uid]</u>
PromotionLink to the documentDescriptionLink to the documentDescription	List of publications in HAL <u>http://www.ncbi.nlm.nih.gov/pubmed/?</u> <u>term=%28cesame+AND+Beaugerie[Author]%29+</u> <u>OR+22157331[uid]</u>
PromotionLink to the documentDescriptionLink to the documentDescriptionAccessTerms of data access (charter for data provision, format of	List of publications in HAL <u>http://www.ncbi.nlm.nih.gov/pubmed/?</u> <u>term=%28cesame+AND+Beaugerie[Author]%29+</u> <u>OR+22157331[uid]</u> List of publications in Pubmed Data may be used by academic teams Data may be
PromotionLink to the documentDescriptionLink to the documentDescriptionAccessTerms of data access (charter for data provision, format of data, availability delay)	List of publications in HALhttp://www.ncbi.nlm.nih.gov/pubmed/? term=%28cesame+AND+Beaugerie[Author]%29+ OR+22157331[uid]List of publications in PubmedData may be used by academic teams Data may be used by industrial teams